©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Characterization of the in Vivo Phosphorylation Sites of the mRNACap-binding Complex Proteins Eukaryotic Initiation Factor-4E and p20 in Saccharomyces cerevisiae(*)

(Received for publication, July 27, 1995; and in revised form, August 16, 1995)

Nilson I. T. Zanchin John E. G. McCarthy (§)

From the Department of Gene Expression, National Biotechnology Research Centre (GBF), Mascheroder Weg 1, D-38124 Braunschweig, Federal Republic of Germany

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

Eukaryotic translation is believed to be regulated via the phosphorylation of specific eukaryotic initiation factors (eIFs), including one of the cap-binding complex proteins, eIF-4E. We show that in the yeast Saccharomyces cerevisiae, both eIF-4E and another cap-binding complex protein, p20, are phosphoproteins. The major sites of phosphorylation of yeast eIF-4E are found to be located in the N-terminal region of its sequence (Ser^2 and Ser) and are thus in a different part of the protein from the main phosphorylation sites (Ser and Ser) proposed previously for mammalian eIF-4E. The most likely sites of p20 phosphorylation are at Ser and/or Ser. All of the major sites in the two yeast proteins are phosphorylated by casein kinase II in vitro. Casein kinase II phosphorylation of cap-complex proteins should therefore be considered as potentially involved in the control of yeast protein synthesis. Mutagenesis experiments revealed that yeast eIF-4E activity is not dependent on the presence of Ser^2 or Ser. On the other hand, we observed variations in the amount of (phosphorylated) p20 associated with the cap-binding complex as a function of cell growth conditions. Our results suggest that interactions of yeast eIF-4E with other phosphorylatable proteins, such as p20, could play a pivotal role in translational control.


INTRODUCTION

The eukaryotic initiation factor (eIF)(^1)-4E (eIF-4Falpha) is an essential component of the eukaryotic translation apparatus. eIF-4E constitutes part of the so-called cap-binding complex eIF-4F which, in higher eukaryotes, also contains eIF-4A and p220(1) . This complex, together with eIF-4B, promotes binding of the 43S preinitiation complex to mRNA(2, 3) . The yeast Saccharomyces cerevisiae does not possess a cap-binding complex directly equivalent to mammalian eIF-4F. Instead, yeast eIF-4E has been shown to form a complex with two other proteins, p150 (believed to be the homologue of p220) and p20, whose functions are as yet unknown(4, 5, 6, 7) . However, up to now it has been assumed that yeast eIF-4F fulfils the same function(s) as its mammalian counterpart.

The sequencing of several eIF-4E genes has revealed strong homology within the group of known mammalian polypeptide sequences and less extensive, but clearly evident, homology between the yeast eIF-4E sequence and the sequences of the counterpart proteins of mammals and wheat. The mammalian and yeast proteins are immunologically distinct (8) . However, mouse eIF-4E (9) can substitute for the yeast protein in vivo. Thus, there is also at least partial functional homology between the various eIF-4E proteins. At the same time, the functional role(s) of eIF-4E is(are) incompletely defined. Certain reports have already indicated that this protein might be directly or indirectly involved in a number of processes other than translation. For example, the yeast eIF-4E gene has been identified as the locus of a cell-cycle mutation (cdc 33) that arrests the mitotic cycle at the ``start'' stage(10) . Moreover, a fraction of the cellular population of eIF-4E in COS-1 cells (11) and in yeast (12) localizes to the nucleus.

One striking property of mammalian eIF-4E is that its overproduction can lead to the transformation of higher cells(13, 14) . Moreover, increased levels of this initiation factor allow enhanced translation of mRNAs whose leaders bear strongly inhibitory secondary structure (15) . On the other hand, the overproduction of yeast eIF-4E has little effect on growth or on translation limited by mRNA structure in S. cerevisiae(12) .

Various lines of evidence indicate that the phosphorylation state of eukaryotic initiation factors can influence their activities in translation(2) . The most convincing case so far is that of eIF-2. Phosphorylation of the alpha subunit of this factor by specific kinases at serine 51 in mammals (2) and yeast (16) inhibits the exchange of GTP/GDP and effectively reduces the activity of eIF-2. Phosphorylation of other sites in the C-terminal region of eIF-2alpha by casein kinase II also influences eIF-2 activity, albeit in a more subtle manner(17, 18) . Increased phosphorylation of eIF-4E, in contrast, seems to correlate with enhanced translational rates(19, 20, 21, 22, 23, 24, 25) . Conversely, dephosphorylation has been found to accompany the inhibition of protein synthesis under various conditions(26, 27, 28) . However, these are indirect correlations which are insufficient to prove the existence of a causal link between phosphorylation and the activity of eIF-4E. A more direct demonstration of a functional change associated with phosphorylation was reported by Minich et al.(29) , who found that the phosphorylated form of mammalian eIF-4E has a 3-fold enhanced affinity for the cap.

What is(are) the site(s) of phosphorylation in eIF-4E? Ser was identified as a residue whose mutation to alanine nullifies certain properties of the wild-type factor(30) . Thus, whereas the overproduction of wild-type eIF-4E induced aberrant growth in rodent and Hela cells, this effect was not observed when the Ala mutant was used(13, 14) . Similarly, overexpression of the wild-type gene, but not of the Ala mutant form, seemed to allow enhanced translation of mRNAs with structured leaders in mouse cells(15) . It was also reported that the Ala mutation prevents incorporation of eIF-4E into the 48 S initiation complex(31) . Certain lines of evidence have indicated that eIF-4E may be phosphorylated by protein kinase C(21, 22, 23, 24) , and this enzyme has therefore been assumed to be involved in the regulation of eIF-4E activity.

However, conflicting evidence has thrown doubt on the significance of phosphorylation at position 53 in the mammalian eIF-4E amino acid sequence. It was observed that mutation of Ser to Ala did not affect the phosphorylation level of transiently overexpressed eIF-4E in COS-1 monkey kidney cells(32) . These authors also detected no effects of the overexpression of either wild-type or mutant forms of mammalian eIF-4E on translational initiation in this cell type. This therefore suggests that there may be an alternative explanation of the results obtained by others using Ser mutation(s). For example, the Ser to Ala substitution at position 53 may result in a conformational mutant form of eIF-4E with altered properties that are unrelated to the phosphorylation state of this factor. Indeed, it was more recently reported that the major site of phosphorylation in mammalian eIF-4E is Ser(33) .

Up to now, there has been no information available about the phosphorylation sites in the yeast cap-binding complex eIF-4F. Given the widely acknowledged significance of S. cerevisiae as an experimental organism for studies of translation, as well as the uncertainty surrounding the results obtained so far with the mammalian factor, it has become especially important to investigate eIF-4F phosphorylation in this lower eukaryote. We have used biochemical and genetic techniques to show that both eIF-4E and p20 in yeast are phosphoproteins and that they are phosphorylated by the same kinase. We examine the functional significance of these phosphorylation events. The results provide a new perspective on the pathway and role of phosphorylation in the regulation of the eukaryotic mRNAbulletcap-binding complex eIF-4F.


MATERIALS AND METHODS

Bacterial and Yeast Strains, Genetic and Protein Methods

Escherichia coli TG2 strain (supE44 hsdDelta4 thiDelta(lac-proAB)Delta(srlrecA)306:: Tn10 (tet`) F` (traD36 proAB lacI lacZDeltaM15(34) ) and S. cerevisiae 20B-12 (trp1 pep4-3(35) ) and 4-2 (a eIF-4E::LEU2 ura3 trp1 leu2 (pMDA101 eIF-4E Glu> Lys, Gly> Asp)(36) ) strains were used. The deletion constructs eIF-4EDel7 and eIF-4EDel19 were kindly provided by Simona Vasilescu. Bacterial media and DNA cloning and sequencing techniques were performed as described previously(34) . Yeast media were prepared as described by Sherman et al.(37) . YEPD low phosphate medium was prepared according to Rubin(38) . Both E. coli and S. cerevisiae were transformed by electroporation. SDS-polyacrylamide gel electrophoresis (39) and Western blotting (40) were performed as described. Isoelectrofocusing was adapted from Dever et al.(41) . The ampholytes were a mixture of 4:1 of the pH ranges 5-7:3-10. Quantitation of eIF-4E and p20 protein and of their phosphorylation was performed via analysis of SDS-polyacrylamide gel electrophoresis gels and autoradiography using an image analyzer. Total protein synthesis was determined by measuring [S]L-methionine incorporation rates in minimal medium (SD medium(37) ).

Plasmid Constructs, eIF-4E Expression, and in Vivo Labeling

The plasmid pCYTEXP1 (42) was used for synthesis of eIF-4E in E. coli and for isolating single-stranded DNA for in vitro mutagenesis. The yeast eIF-4E gene was inserted into this vector as an NdeI-BamHI restriction fragment(12) . Recombinant eIF-4E was obtained from E. coli TG2 as described previously(12, 43) . Synthesis of eIF-4E and its mutants in yeast was performed using the GPF promoter plasmid YCpSUPEX1 (44) and the TRP1 promoter plasmid YCp332TRP1. The latter plasmid was constructed by substituting a 1.6-kilobase fragment bearing the TRP1 promoter (45) for the GPF promoter in YCpSUPEX1. The derivatives of these plasmids were introduced into the strain 4-2, after which plasmid shuffling was performed to allow loss of pMDA101. For in vivo labeling, cells were grown in low phosphate medium to an OD = 0.4, centrifuged, and resuspended in fresh medium containing 200 µCi/ml P(i). After incubation for 1.5 h at 30 °C, the cells were washed and resuspended in buffer (20 mM HEPES, pH 7.4, 100 mM KCl, 0.5 mM EDTA, 1 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 5 mM NaF, 5 mM glycerol phosphate) and vortexed with glass beads. The cell debris was removed by centrifugation and the cap-binding complex proteins were isolated from the extracts by means of affinity chromatography using a 7-methyl-GTP-Sepharose column (Pharmacia).

Isolation of Casein Kinase II and in Vitro Phosphorylation

Casein kinase II was purified from strain 4-2 (carrying the wild-type eIF-4E gene in YCpSUPEX1) using a protocoll adapted from Padmanabha and Glover(46) . Yeast cell extracts were fractionated on a Q-Sepharose column. The fractions possessing casein kinase II activity were pooled and run through a heparin-Sepharose affinity column. Finally, the kinase preparation was concentrated on a fast protein liquid chromatography MonoQ column (Pharmacia). The kinase activity assay was performed using beta-casein as acceptor according to Glover et al.(47) , except that the incubation temperature was 30 °C. Phosphorylation assays were also performed using recombinant eIF-4E or cap-binding proteins isolated from yeast instead of beta-casein.

Phosphoamino Acid Analysis, Phosphopeptide Mapping, and HPLC Analysis

Phosphoamino acid analysis and two-dimensional peptide analysis were performed on thin layer cellulose plates (Kodak)(48, 49) . For HPLC analysis, 200 µl (about 2 nmol) of eIF-4E tryptic peptides were applied to a reverse-phase C(18) column (Waters-Millipore) and eluted over a period of 80 min using a 5-50% acetonitrile gradient (flow-rate = 0.5 ml/min).


RESULTS AND DISCUSSION

eIF-4E and p20 in Yeast Are Phosphoproteins

In order to determine whether yeast eIF-4E is phosphorylated in vivo, we added P(i) to shaking cultures of log-phase yeast. After a period of incubation of 90 min, cell extracts were prepared and subjected to affinity chromatography. Separation of the cap-binding complex proteins using SDS-polyacrylamide gel electrophoresis and analysis using autoradiography revealed that both p20 and eIF-4E are phosphoproteins, whereby the former was approximately 10 times more strongly labeled than the latter (Fig. 1, A and B). Isoelectrofocussing of labeled extracts yielded various bands in the pH range 5.6 to 6.0 detectable by immunoblotting using eIF-4E-antibody (Fig. 1E). Only one of these bands, slightly more acidic than the major one, could be detected by autoradiography. We therefore conclude that only a small fraction of the total eIF-4E is phosphorylated in vivo. The additional bands to the basic side of the major one may correspond to eIF-4E degradation products, which were routinely observed in preparations of this protein, or to heterogeneity caused by other types of protein modification (compare (31) ). Phosphoamino acid analysis showed that the amino acids phosphorylated in p20 and eIF-4E are in both cases serine residues (Fig. 2A).


Figure 1: In vivo labeling of eIF-4E and p20 with P(i). A and B, SDS-polyacrylamide gel and autoradiograph, respectively, of eIF-4E and p20 labeled in vivo. LP, log-phase-growing cells were labeled as described under ``Materials and Methods.'' HS, in vivo labeling during heat shock. The cells were grown up to the desired OD at 28 °C and then incubated with 200 µCi/ml P(i) at 37 °C for 1.5 h. SP, proteins isolated from cells labeled in the stationary phase. The cells were grown up to stationary phase, then 200 µCi/ml P(i) was added to the culture, which was incubated for another 1.5 h at 30 °C. C and D, SDS-polyacrylamide gel and autoradiograph, respectively, of proteins isolated from yeast strains bearing eIF-4E mutant genes labeled in vivo. S2A, eIF-4E serine 2 alanine mutant; S2+15A, serine 2 and alanine 15 double mutant; del19, N-terminal mutant deleted up to amino acid position 19. E, isoelectrofocusing of wild-type eIF-4E labeled in vivo. 1, Western blot; 2, autoradiography.




Figure 2: Phosphoamino acid analysis. A, in vivo labeled eIF-4E and p20 proteins were subjected to partial acid hydrolysis and the phosphoamino acids analyzed by electrophoresis on cellulose plates using a buffer system at pH 3.5. B, phosphoamino acid analysis of proteins labeled in vitro with casein kinase II. R-WT and R-S2+15A, recombinant wild-type and double mutant serine 2 and 15 to alanine eIF-4E, both isolated from E. coli. The lanes labeled with the prefix Y are analyses of proteins isolated from yeast: WT and S2+15A eIF-4E wild-type and double mutant; and p20. The positions of the phosphoamino acids used as standards (P-Ser (P-S), P-Thr (P-T), and P-Tyr (P-Y)) as well as phosphate (P(i)) and the origin (OR) are indicated. Partial hydrolysis products are visible in certain lanes.



Mapping the Phosphorylation Sites in eIF-4E

P-Labeled eIF-4E was isolated from strain 20B-12, which has a wild-type chromosomal eIF-4E gene, or from strain 4-2 transformed with the wild-type gene in the plasmid YCpSUPEX1, and subjected to tryptic digestion. The resulting peptides were analyzed using two-dimensional peptide mapping and HPLC. Two-dimensional peptide mapping revealed two major and several weakly labeled phosphopeptides (Fig. 3, WT). The more strongly labeled peptide (peptide 1, Fig. 3) migrates slightly further toward the cathode than the neutral marker -dinitrophenyl-lysine (dnp-lysine). This behavior would be expected of either a positively charged peptide or, in the case of a neutral peptide, might be explained on the basis of endoosmotic effects(48) . The second major phosphopeptide (peptide 2, Fig. 3) moves about the same distance as xylene-cyanol toward the anode. This marker has a negative charge at pH 3.5. Other weakly labeled peptides can be seen close to peptide 1. A further peptide migrates close to dnp-lysine (peptide 3, Fig. 3) and is evidently relatively hydrophobic.


Figure 3: Two-dimensional phosphopeptide mapping of eIF-4E wild-type and mutants. In vivo labeled eIF-4E protein was digested with trypsin and analyzed by electrophoresis (1st dimension) and chromatography (2nd dimension) on cellulose plates. The positions of -dinitrophenyl-lysine (dnp-K) and xylene-cyanol (XC) used as standards, and the origin (), are indicated. WT, wild-type eIF-4E; Del7, N-terminal deletion up to amino acid position 7; S2A, serine 2-alanine mutant; S7A, serine 7-alanine mutant; S15A, serine 15-alanine mutant; S2+15A, double mutant serine 2 and 15-alanine. The phosphopeptides referred to in the text are numbered.



HPLC analysis of the tryptic peptides derived from in vivo phosphorylated eIF-4E also yielded two major radioactive peaks, plus four weaker ones (Fig. 4), consistent with the data obtained from two-dimensional peptide mapping. Thus, the above analytical methods indicated the existence of at least two major (serine) phosphorylation sites in yeast eIF-4E. We attempted to identify the phosphorylated peptides in the two major fractions via peptide sequencing. However, the low level of labeling combined with the incomplete separation of the peptides prevented us from obtaining unequivocal data, and we turned to an alternative approach.


Figure 4: HPLC analysis of peptides generated by tryptic digestion of eIF-4E labeled in vivo. A, profile of the 80 min 5-50% acetonitrile gradient (A, flow-rate 0.5 ml/min). B, quantitation of the radioactivity of the fractions collected during the run shown in A. The elution positions of the radioactive peaks identified in B are indicated in A.



Identification of the Phosphorylated Serines in eIF-4E

Analysis of the eIF-4E protein sequence reveals the existence of several potential phosphorylation sites in the N-terminal region of the protein. Ser^7 is located in a theoretical consensus site for both casein kinase I and protein kinase C-like kinases, while Ser^2 lies in a consensus sequence for casein kinase II and Ser in a sequence expected to be recognized by both casein kinase I and II (Fig. 6). An initial crude test of phosphorylation in this region was to make use of two N-terminal deletion mutants which have lost two or more of the initial serines in the amino acid sequence. (^2)In vivo labeling was performed using derivatives of 4-2 bearing each of the deletion mutants. Both of these deletion mutant proteins were able to support translation in vivo.^2 eIF-4EDel7 was found to be less strongly labeled than the wild-type protein, and tryptic peptide analysis revealed that phosphopeptide 2 was no longer present (Fig. 3, Del7). Phosphorylation of the eIF-4EDel19 mutant, moreover, was hardly detectable (Fig. 1, C and D, and 5). In order to define the phosphoserine residues precisely, we constructed point mutants in which one or more of the N-terminal serines has been mutated to alanine(s). Mutation of Ser^7 to Ala (S7A) did not change the labeling pattern observed (Fig. 3, S7A). However, further phosphopeptide mapping analyses of the single mutants S2A and S15A, as well as the double mutant S2+15A, clearly showed that Ser^2 and Ser are the major phosphorylation sites of eIF-4E in S. cerevisiae grown under the described conditions. The major labeled peptides were removed only in the double mutant S2+15A (Fig. 1, C and D and Fig. 3, S2+15A). Moreover, phosphorylation of the double mutant form of eIF-4E was reduced by more than 80% in vivo (Fig. 5). The remaining spot in the area of peptide 1 observed with the S15A mutant (Fig. 3) was one of the weakly labeled phosphopeptides (see previous section and Fig. 3and Fig. 4) generated by tryptic digestion with a similar mobility to peptide 1. It is also evident in the map of the double mutant (S2+15A).


Figure 6: Confirmed and potential phosphorylation sites in the S. cerevisiae cap-complex proteins eIF-4E and p20. Shown are the N-terminal (indicated by the subscript N) amino acid sequence of eIF-4E, and the two regions of the now corrected version of the p20 amino acid sequence containing potential CK-II sites. The serines that were mutated to alanines in the eIF-4E mutants are numbered, and the positions of the start codons of the deletion mutants eIF-4EDel7 and eIF-4EDel19 are indicated by arrowheads. The serines in the revised p20 reading frame suspected to be phosphorylated by CK-II are also numbered.




Figure 5: The phosphorylation of eIF-4E in vivo. Mutant derivatives in which serine phosphorylation sites have been eliminated (compare Fig. 3) are compared to wild-type. The measured values of protein and P incorporation for wild-type eIF-4E (averages of two independent experiments) were each normalized to 1, and the equivalent data obtained with the three mutants were expressed as fractions of the wild-type values. See Fig. 1for an explanation of the strain nomenclature. Light shaded, protein; dark shaded, radioactivity.



Identification of the two phosphorylated serines at positions 2 and 15 via mutational analysis also provides an explanation of the observed mobilities of the phosphopeptides in two-dimensional mapping (Fig. 3; compare Fig. 6). These mobilities are consistent with the expected cleavage sites of trypsin in the eIF-4E amino acid sequence (compare Ref 48). For example, phosphopeptide 1 could be generated by tryptic cleavage at Lys and at either Lys^8 (expected net charge +1 at pH 3.5) or at Lys^9 (neutral). Phosphopeptide 2, on the other hand, could be generated by cleavage at Lys^8 (expected net charge -1).

We investigated whether there was a growth phenotype associated with the double mutation in eIF-4E. Expression of the mutant gene in strain 4-2 lacking the wild-type eIF-4E gene allowed growth at a rate reduced by no more than 5% relative to wild-type under standard growth conditions both in YEPD and minimal medium. We also investigated the rates of total protein synthesis in whole cells (measured as [S]L-methionine incorporation) containing only the S2+15A mutant (data not shown). A decrease of less than 10% compared to the equivalent strain bearing wild-type eIF-4E was detectable during log-phase growth at 30 °C or under heat shock conditions (39 °C).

It might be argued that the described mutations induce changes in the phosphorylation state of eIF-4E via indirect conformational changes. However, this is unlikely for at least three reasons. First, each of the single mutations, S2A and S15A, eliminates the phosphorylation of one specific peptide, and the combination of both mutations results in an additive effect (Fig. 3), whereas S7A has no effect on the phosphorylation pattern. Second, the results obtained with the deletion mutants Del7 and Del19 are fully consistent with the former observations ( Fig. 3and Fig. 5), despite the fact that deletions of this kind would be more likely to induce significant conformational alterations in the overall structure of the protein. Third, the fact that none of the amino acid substitutions have a readily detectable phenotype under log-phase growth conditions indicates that if they do cause conformational changes in the protein these are probably small.

Both eIF-4E and p20 Are Phosphorylated by Casein Kinase II

The two phosphorylated serines identified lie in potential casein kinase II sites. Casein kinase II was isolated from yeast and used for in vitro phosphorylation reactions. Recombinant wild-type and S2+15A eIF-4E proteins were isolated from E. coli and used as substrates. The mutant was weakly labeled compared to the wild-type protein (Fig. 7A). Phosphoamino acid analysis revealed that both proteins were phosphorylated at serine residues (Fig. 2B, R lanes). One of the phosphopeptides (data not shown) generated by tryptic digestion corresponds to the major site of phosphorylation in vivo (peptide 1; see Fig. 3) and is not present in the peptide map of the S2+15A mutant. The other major phosphopeptide observed, which is present in the maps of both proteins, is located at the same position as the weakly labeled peptide obtained from the in vivo phosphorylated protein which is located close to dnp-lysine (see peptide 3, Fig. 3). Unexpectedly, no phosphopeptide derived from wild-type recombinant eIF-4E was observed at the position corresponding to peptide 2.


Figure 7: Phosphorylation in vitro using casein kinase II. A, autoradiograph of a time course of the in vitro phosphorylation of recombinant wild-type (WT) and double mutant serine 2 and 15-alanine eIF-4E (S2+15A). B, autoradiograph of a time course of the in vitro phosphorylation of cap-binding proteins isolated from yeast strains bearing either the wild-type or the double mutant eIF-4E gene. The positions of eIF-4E and p20 are indicated. The other larger molecular weight bands are attributable to autophosphorylation of casein kinase II. C, comparison of the results of incubation of wild-type recombinant eIF-4E (4E) with casein kinase II for 20 min at 30 °C and an equivalent control experiment lacking eIF-4E as substrate (C).



In light of the above discrepancy between the in vitro and in vivo labeling, we isolated cap-binding complexes from yeast cells containing either the wild-type or the S2+15A mutant and phosphorylated the resulting preparations in vitro using casein kinase II. The two major phosphopeptides 1 and 2 observed in the maps prepared from in vivo labeled wild-type eIF-4E could again be observed in the wild-type, but not in the S2+15A mutant (Fig. 8, panels WT and S2+15A). In conclusion, casein kinase II can phosphorylate both Ser^2 and Serin vitro. The difference in substrate behavior of recombinant eIF-4E from E. coli might be due to an altered conformation relative to that of the natural yeast protein. Alternatively, the association of other yeast proteins, such as p20, with eIF-4E isolated from yeast might influence the accessibility of site 2. The relative strengths of peptides 2 and 3 are reversed in the in vitro and in vivo labeling of yeast eIF-4E (compare Fig. 8and Fig. 3, WT). Ser^2 is evidently poorly phosphorylated in vitro, whereas the third site (peptide 3) seems to be a better substrate.


Figure 8: Phosphopeptide mapping of eIF-4E and p20 isolated from yeast and phosphorylated in vitro using casein kinase II. WT and S2+15A, eIF-4E wild-type and double mutant, respectively. p20 in vivo, peptide mapping of p20 labeled in vivo; p20 in vitro, peptide mapping of p20 phosphorylated in vitro using casein kinase II. The positions of the eIF-4E phosphopeptides 1-3, the major (A) and minor (B) phosphopeptides of p20, the standards -dinitrophenyl-lysine (dnp-K) and xylene-cyanol (XC), and of the origin () are indicated.



A striking aspect of the in vitro phosphorylation of the cap-binding complex isolated from yeast is that p20 is very rapidly labeled, apparently becoming fully phosphorylated after 5 min of incubation under the conditions described (Fig. 7B). In the process of analyzing the potential sites of phosphorylation in p20, we discovered a discrepancy in the gene sequence compared with that published previously. Our sequencing analysis revealed the existence of an additional A nucleotide in the series of As(370-374) in the published reading frame(51) . The revised reading frame encodes a protein of 161 amino acids and contains two apparent casein kinase II consensus sequences at serines 91 and 154 (Fig. 6). Phosphoamino acid analysis of p20 (Fig. 2), together with peptide mapping of this protein labeled in vivo and in vitro (Fig. 8), indicates that casein kinase II is the major enzyme responsible for p20 phosphorylation in vivo. The in vivo peptide mapping data reveal the existence of at least one major (peptide A), and one minor (peptide B), phosphorylation site in p20. The same major phosphopeptide (A) was also generated by tryptic digestion of p20 that had been phosphorylated by casein kinase II in vitro (Fig. 8).

The Phosphorylated eIF-4F Complex in Vivo: Potential Regulatory Pathways

The phosphorylation state of eIF-4E was analyzed under different culture conditions. The amount of P-labeled eIF-4E in the isolated cap-binding complex was unaffected by heat shock (Fig. 1, A and B, and 9) or the addition of cycloheximide (data not shown). The level of eIF-4E phosphorylation in the stationary phase appears, at first sight, to have increased. However, this change in the specific labeling intensity was primarily due to the depletion of unlabeled phosphate observed under these conditions. More striking was the observation that the amount of phosphorylated p20 associated with eIF-4E was increased under conditions of heat shock or cycloheximide treatment, whereas reduced amounts were observed in extracts from cells in the stationary phase (Fig. 1, A and B, and 9). The true reduction in the degree of phosphorylation of p20 in stationary phase, for the reason mentioned above, must be significantly greater than that indicated in Fig. 9. We do not know which of the potential phosphorylation sites in p20 is(are) involved in the overall changes in phosphorylation level.


Figure 9: Phosphorylation of eIF-4E and p20 in vivo during log phase growth (LP), heat shock (HS), and stationary phase (ST). The amounts of eIF-4E or p20 and of P incorporation into these proteins are expressed as values relative to the log-phase growth data (normalized to 1.0).



The results described in this paper show that eIF-4E and p20 in yeast are at least partially phosphorylated in vivo. The level of phosphorylation of eIF-4E detected was particularly low, with most of this factor being present in the non-phosphorylated form. The pattern of phosphorylation was unexpected. The major positions of phosphorylation of eIF-4E are not protein kinase C sites and are not equivalent to the sites reported to be present in the mammalian counterpart protein. Instead, casein kinase II, a serine/threonine kinase ubiquitously present in eukaryotic cells, has been found to phosphorylate both proteins. This kinase has a wide range of substrates, including proteins linked to the cell-cycle, cell growth, and cell differentiation(52) . In yeast, casein kinase II is essential for cell viability, and there is evidence for its involvement in cell-cycle regulation(53) . For example, casein kinase II phosphorylation of yeast topoisomerase II is cell-cycle-dependent(54) . Here, as in yeast eIF-2alpha(17, 18) , the phosphorylation sites are close to the C terminus of the protein. The main casein kinase II phosphorylation sites of yeast eIF-4E are close to the N terminus, and one of the p20 sites is predicted to be close to the C terminus (Fig. 6). Mutation of the two major phosphorylation sites in eIF-4E results in only a minimal phenotype in yeast under standard growth conditions. Indeed, yeast can survive with an eIF-4E protein that has no detectable phosphorylation (see Fig. 5). In this context, it is significant that the mutation of Ser to Ala in mammalian eIF-4E has no effect on this factor's association with the 48 S initiation complex(33) . However, as with eIF-2alpha(17) , our data do not rule out that there are conditions under which such sites are functionally important. Of at least equal importance is the observed variation in binding of phosphorylated p20 to eIF-4E, which will need to be investigated in considerable detail.

In conclusion, this study establishes the necessity to reassess the pathway and regulation of phosphorylation of yeast (and possibly mammalian) eIF-4E. Indeed, the variations in the amount of phosphorylated p20 we have described suggest that the possible involvement of other proteins that interact with eIF-4E may play important regulatory roles in translational initiation. We see here a potential parallel to the recently described regulatory system for mammalian eIF-4E. The binding of PHAS-I to mammalian eIF-4E is regulated via phosphorylation of Ser in the regulatory protein by mitogen-activated kinase(50, 55) . Thus, the mitogen-induced stimulation of protein synthesis is thought to be mediated via this regulator binding mechanism. On the basis of our new data on the yeast cap-binding proteins, future work will need to explore analogous paths for potential regulatory mechanisms in this lower eukaryote.


FOOTNOTES

*
We thank the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) of Brazil for a stipend (to N. I. T. Z.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed. Tel.: 0531-6181-430; Fax: 0531-6181-458.

(^1)
The abbreviations used are: eIF, eukaryotic initiation factor; HPLC, high performance liquid chromatography; dnp, dinitrophenyl.

(^2)
S. Vasilescu, M. Ptushkina, P. P. Müller, and J. E. G. McCarthy, manuscript submitted for publication.


ACKNOWLEDGEMENTS

Simona Vasilescu kindly provided the two mutants eIF-4EDel7 and eIF-4EDel19.


REFERENCES

  1. Sonenberg, N. (1988) Prog. Nucleic Acids Res. Mol. Biol. 35, 175-204
  2. Hershey, J. W. B. (1991) Annu. Rev. Biochem. 60, 717-755 [CrossRef][Medline] [Order article via Infotrieve]
  3. Merrick, W. C. (1992) Microbiol. Rev. 56, 291-315 [Abstract]
  4. Altmann, M., and Trachsel, H. (1994) Trends Biol. Sci. 18, 429-432
  5. Goyer, C., Altmann, M., Trachsel, H., and Sonenberg, N. (1989) J. Biol. Chem. 264, 7603-7610 [Abstract/Free Full Text]
  6. Lanker, S., Müller, P. P., Altmann, M., Goyer, C., Sonenberg, N., and Trachsel, H. (1992) J. Biol. Chem. 267, 21167-21171 [Abstract/Free Full Text]
  7. Goyer, C., Altmann, M., Lee, H. S., Blanc, A., Deshmukh, M., Woolford, J. L., Trachsel, H., and Sonenberg, N. (1993) Mol. Cell. Biol. 13, 4860-4874 [Abstract]
  8. Altmann, M., Edery, I., Sonenberg, N., and Trachsel, H. (1985) Biochemistry 24, 6085-6089 [Medline] [Order article via Infotrieve]
  9. Altmann, M., Müller, P. P., Pelletier, J., Sonenberg, N., and Trachsel, H. (1989) J. Biol. Chem. 264, 12145-12147 [Abstract/Free Full Text]
  10. Brenner, C., Nakayama, N., Goebl, M., Tanaka, K., Toh-e, A., and Matsumoto, K. (1988) Mol. Cell. Biol. 8, 3556-3559 [Medline] [Order article via Infotrieve]
  11. Lejbkowicz, F., Goyer, C., Darveau, A., Neron, S., Lemieux, R., and Sonenberg, N. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 9612-9616 [Abstract]
  12. Lang, V., Zanchin, N. I. T., Lünsdorf, H., Tuite, M., and McCarthy, J. E. G. (1994) J. Biol. Chem. 269, 6117-6123 [Abstract/Free Full Text]
  13. Lazaris-Karatzas, A., Montine, K. S., and Sonenberg, N. (1990) Nature 345, 544-547 [CrossRef][Medline] [Order article via Infotrieve]
  14. De Benedetti, A., and Rhoads, R. E. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 8212-8216 [Abstract]
  15. Koromilas, A. E., Lazaris-Karatzas, A., and Sonenberg, N. (1992) EMBO J. 11, 4153-4158 [Abstract]
  16. Hinnebusch, A. G. (1994) Trends Biochem. Sci. 19, 409-414 [CrossRef][Medline] [Order article via Infotrieve]
  17. Feng, L., Yoon, H., and Donahue, T. F. (1994) Mol. Cell. Biol. 14, 5139-5153 [Abstract]
  18. van den Heuvel, J., Lang, V., Richter, G., Price, N., Peacock, L., Proud, C., and McCarthy, J. E. G. (1995) Biochim. Biophys. Acta 1261, 337-348 [Medline] [Order article via Infotrieve]
  19. Rinker-Schaeffer, C. W., Austin, V., Zimmer, S., and Rhoads, R. E. (1992) J. Biol. Chem. 267, 10659-10664 [Abstract/Free Full Text]
  20. Frederickson, R. M., Montine, K. S., and Sonenberg, N. (1991) Mol. Cell. Biol. 11, 2896-2900 [Medline] [Order article via Infotrieve]
  21. Morley, S. J., and Traugh, J. A. (1989) J. Biol. Chem. 264, 2401-2404 [Abstract/Free Full Text]
  22. Morley, S. J., and Thomas, G. (1991) Pharmacol. & Ther. 50, 291-319
  23. Morley, S. J., and Traugh, J. A. (1993) Biochimie (Paris) 75, 985-989 [CrossRef][Medline] [Order article via Infotrieve]
  24. Morley, S. J., Rau, M., Kay, J. E., and Pain, V. M. (1993) Eur. J. Biochem. 218, 39-48 [Abstract]
  25. Donaldson, R. W., Hagedorn, C. H., and Cohen, S. (1991) J. Biol. Chem. 266, 3162-3166 [Abstract/Free Full Text]
  26. Duncan, R., Milburn, S. C., and Hershey, J. W. B. (1987) J. Biol. Chem. 262, 380-388 [Abstract/Free Full Text]
  27. Feigenblum, D., and Schneider, R. J. (1993) J. Virol. 67, 3027-3035 [Abstract]
  28. Zhang, Y., Feigenblum, D., and Schneider, R. J. (1994) J. Virol. 68, 7040-7050 [Abstract]
  29. Minich, W. B., Balasta, M. L., Goss, D. J., and Rhoads, R. E. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 7668-7672 [Abstract]
  30. Rychlik, W., Russ, M. A., and Rhoads, R. E. (1987) J. Biol. Chem. 262, 10434-10437 [Abstract/Free Full Text]
  31. Joshi-Barve, S., Rychlik, W., and Rhoads, R. E. (1990) J. Biol. Chem. 265, 2979-2983 [Abstract/Free Full Text]
  32. Kaufmann, R. J., Murtha-Riel, P., Pittman, D. D., and Davies, M. V. (1993) J. Biol. Chem. 268, 11902-11909 [Abstract/Free Full Text]
  33. Joshi, B., Cai, A.-L., Keiper, B. D., Minich, W. B., Mendez, R., Beach, C. M., Stepinski, J., Stolarski, R., Darzynkiewicz, E., and Rhoads, R. E. (1995) J. Biol. Chem. 270, 14597-14603 [Abstract/Free Full Text]
  34. Sambrook, J., Maniatis, T., and Fritsch, E. F. (1989) Molecular Cloning: A Laboratory Manual , 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
  35. Jones, E. W. (1976) Genetics 85, 23-33
  36. Altmann, M., Sonenberg, N., and Trachsel, H. (1989) Mol. Cell. Biol. 9, 4467-4472 [Medline] [Order article via Infotrieve]
  37. Sherman, F., Fink, G. R., and Hicks, J. B. (1986) Laboratory Course Manual for Methods in Yeast Genetics , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
  38. Rubin, G. M. (1973) J. Biol. Chem. 248, 3860-3875 [Abstract/Free Full Text]
  39. Laemmli, U. K. (1979) Nature 227, 680-685
  40. Towbin, H., Stachelin, T., and Gordon, J. (1979) Proc. Natl. Acad. Sci. U. S. A. 76, 4350-4354 [Abstract]
  41. Dever, T. E., Feng, L., Wek, R. C., Cigan, A. M., Donahue, T. F., and Hinnebusch, A. G. (1992) Cell 68, 585-596 [Medline] [Order article via Infotrieve]
  42. Belev, T. N., Singh, M., and McCarthy, J. E. G. (1991) Plasmid 26, 147-150 [Medline] [Order article via Infotrieve]
  43. Edery, I., Altmann, M., and Sonenberg, N. (1988) Gene (Amst.) 74, 517-525 [CrossRef][Medline] [Order article via Infotrieve]
  44. Oliveira, C. C., van den Heuvel, J. J., and McCarthy, J. E. G. (1993) Mol. Microbiol. 9, 521-532 [Medline] [Order article via Infotrieve]
  45. Dobson, M. J., Tuite, M. F., Mellor, J., Roberts, N. A., King, R. M., Burke, D. C., Kingsman, A. J., and Kingsman, S. M. (1983) Nucleic Acids Res. 11, 2287-2302 [Abstract]
  46. Padmanabha, R., and Glover, C. V. C. (1987) J. Biol. Chem. 262, 1829-1835 [Abstract/Free Full Text]
  47. Glover, C. V. C., Shelton, E. R., and Brutlag, D. L. (1983) J. Biol. Chem. 258, 3258-3265 [Abstract/Free Full Text]
  48. Boyle, W. J., van der Geer, P., and Hunter, T. (1991) Methods Enzymol. 201, 110-148 [Medline] [Order article via Infotrieve]
  49. van der Geer, P., Luo, K., Sefton, B. M., and Hunter, T. (1993) in Protein Phosphorylation: A Practical Approach (Hardie, D. G., ed) pp. 31-58, IRL Press, Oxford, United Kingdom
  50. Pause, A., Belsham, G. J., Gingras, A.-C., Donze, O., Lin, T.-A., Lawrence, J. C., Jr., and Sonenberg, N. (1994) Nature 371, 762-767 [CrossRef][Medline] [Order article via Infotrieve]
  51. Altmann, M., Krieger, M., and Trachsel, H. (1989) Nucleic Acids Res. 17, 7520 [Medline] [Order article via Infotrieve]
  52. Pinna, L. A. (1990) Biochem. Biophys. Acta 1054, 267-284 [Medline] [Order article via Infotrieve]
  53. Padmanhabha, R., Chen-Wu, J. L.-P., Hanna, D. E., and Glover, C. V. C. (1990) Mol. Cell. Biol. 10, 4089-4099 [Medline] [Order article via Infotrieve]
  54. Cardenas, M. E., Dang, Q., Glover, C. V. C., and Gasser, S. M. (1992) EMBO J. 11, 1785-1796 [Abstract]
  55. Lin, T.-A., Kang, X., Haystead, T. A. Y., Pause, A., and Belsham, G., Sonenberg, N., and Lawrence, J. C., Jr. (1994) Science 266, 653-656 [Medline] [Order article via Infotrieve]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.